Everolimus [EVE5]

Everolimus for advanced renal cell carcinoma after previous treatment

  1. I confirm that an application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy
  2. I confirm that the patient has biopsy proven renal cell carcinoma
  3. I confirm that the patient has progressed during or after treatment with vascular endothelial growth factor targeted therapy
  4. I confirm that the use of everolimus will be as per the Summary of Product Characteristics (SPC)

[NHS funded]{.badge .rounded-pill .bg-success} From: 23 May 2017

Form version:

CDF Managed Access: NA

NICE Technology Appraisal: TA432 (22 February 2017)

Current Form Version

Important

This is an older version of the form. To view the most up to date form follow this link

Older Form Versions

There are previous versions of this form. These may not all be available on this site.